APO Research
Talk to an analyst

APO RESEARCH · REPORT

Softgel CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Softgel CDMO Market Analysis and Forecast 2026-2032

12 August 2026173 pages

Choose your research edition.

Industry ResearchSoftgel CDMO Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Softgel CDMO Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Softgel CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Softgel CDMO Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Softgel CDMO Market Analysis and Forecast 2026-2032173 pages · $4,950 USD

Market perspective

The global Softgel CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Softgel CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Softgel CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Softgel CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Softgel CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Softgel CDMO include Procaps, Patheon, NextPharma, Lonza, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Softgel CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Softgel CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Softgel CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Softgel CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Softgel CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Softgel CDMO revenue, projected growth trends, production technology, application and end-user industry.

Softgel CDMO Segment by Company

Procaps

Patheon

NextPharma

Lonza

Samsung Biologics

Fareva

WuXi AppTech

WuXi Biologics

Siegfried

Catalent

Aenova

Sirio Pharma

Softgel CDMO Segment by Type

Pharmaceutical Softgel CDMO

Nutraceutical Softgel CDMO

Others

Softgel CDMO Segment by Application

Pharmaceutical Company

Biotechnology Company

Others

Softgel CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Softgel CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Softgel CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Softgel CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Softgel CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Softgel CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Softgel CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Softgel CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pharmaceutical Softgel CDMO Major Player Table 3. Nutraceutical Softgel CDMO Major Player Table 4. Others Major Player Table 5. Global Softgel CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Pharmaceutical Company Major Player Table 7. Biotechnology Company Major Player Table 8. Others Major Player Table 9. Softgel CDMO Industry Trends Table 10. Softgel CDMO Industry Drivers Table 11. Softgel CDMO Industry Opportunities and Challenges Table 12. Softgel CDMO Industry Restraints Table 13. Global Softgel CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Softgel CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Softgel CDMO Market Share by Region (2021-2026) Table 16. Global Softgel CDMO Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Softgel CDMO Market Share by Region (2027-2032) Table 18. Global Softgel CDMO Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Softgel CDMO Revenue Market Share by Players (2021-2026) Table 20. Global Softgel CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Softgel CDMO Key Players Headquarters & Area Served Table 22. Global Softgel CDMO Players, Product Type & Application Table 23. Global Softgel CDMO Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Softgel CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Softgel CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Softgel CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Softgel CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Softgel CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Softgel CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Softgel CDMO Revenue Market Share by Application (2027-2032) Table 36. Procaps Company Information Table 37. Procaps Business Overview Table 38. Procaps Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Procaps Softgel CDMO Product Portfolio Table 40. Procaps Recent Development Table 41. Patheon Company Information Table 42. Patheon Business Overview Table 43. Patheon Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Patheon Softgel CDMO Product Portfolio Table 45. Patheon Recent Development Table 46. NextPharma Company Information Table 47. NextPharma Business Overview Table 48. NextPharma Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. NextPharma Softgel CDMO Product Portfolio Table 50. NextPharma Recent Development Table 51. Lonza Company Information Table 52. Lonza Business Overview Table 53. Lonza Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Lonza Softgel CDMO Product Portfolio Table 55. Lonza Recent Development Table 56. Samsung Biologics Company Information Table 57. Samsung Biologics Business Overview Table 58. Samsung Biologics Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Samsung Biologics Softgel CDMO Product Portfolio Table 60. Samsung Biologics Recent Development Table 61. Fareva Company Information Table 62. Fareva Business Overview Table 63. Fareva Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Fareva Softgel CDMO Product Portfolio Table 65. Fareva Recent Development Table 66. WuXi AppTech Company Information Table 67. WuXi AppTech Business Overview Table 68. WuXi AppTech Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. WuXi AppTech Softgel CDMO Product Portfolio Table 70. WuXi AppTech Recent Development Table 71. WuXi Biologics Company Information Table 72. WuXi Biologics Business Overview Table 73. WuXi Biologics Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. WuXi Biologics Softgel CDMO Product Portfolio Table 75. WuXi Biologics Recent Development Table 76. Siegfried Company Information Table 77. Siegfried Business Overview Table 78. Siegfried Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Siegfried Softgel CDMO Product Portfolio Table 80. Siegfried Recent Development Table 81. Catalent Company Information Table 82. Catalent Business Overview Table 83. Catalent Softgel CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Catalent Softgel CDMO Product Portfolio Table 85. Catalent Recent Development Table 86. Aenova Company Information Table 87. Aenova Business Overview Table 88. Aenova Softgel CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Aenova Softgel CDMO Product Portfolio Table 90. Aenova Recent Development Table 91. Sirio Pharma Company Information Table 92. Sirio Pharma Business Overview Table 93. Sirio Pharma Softgel CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Sirio Pharma Softgel CDMO Product Portfolio Table 95. Sirio Pharma Recent Development Table 96. North America Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Softgel CDMO Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Softgel CDMO Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Softgel CDMO Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Softgel CDMO Revenue by Country (US$ Million) & (2027-2032) Table 110. China Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 111. China Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 112. China Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 113. China Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Softgel CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Softgel CDMO Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Softgel CDMO Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Softgel CDMO Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Softgel CDMO Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Softgel CDMO Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Softgel CDMO Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Softgel CDMO Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Softgel CDMO Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Softgel CDMO Image Figure 2. Global Softgel CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Softgel CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pharmaceutical Softgel CDMO Image Figure 5. Nutraceutical Softgel CDMO Image Figure 6. Others Image Figure 7. Global Softgel CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Softgel CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 9. Pharmaceutical Company Image Figure 10. Biotechnology Company Image Figure 11. Others Image Figure 12. Global Softgel CDMO Market Size (US$ Million) & (2021-2032) Figure 13. Global Softgel CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Softgel CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Softgel CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Softgel CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Softgel CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Softgel CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Softgel CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Softgel CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Softgel CDMO Revenue Market Share by Application (2021-2032) Figure 23. North America Softgel CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Softgel CDMO Revenue Share by Type (2021-2032) Figure 25. North America Softgel CDMO Revenue Share by Application (2021-2032) Figure 26. North America Softgel CDMO Revenue Share by Country (2021-2032) Figure 27. United States Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Softgel CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Softgel CDMO Revenue Share by Type (2021-2032) Figure 32. Europe Softgel CDMO Revenue Share by Application (2021-2032) Figure 33. Europe Softgel CDMO Revenue Share by Country (2021-2032) Figure 34. Germany Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Softgel CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Softgel CDMO Revenue Share by Type (2021-2032) Figure 44. China Softgel CDMO Revenue Share by Application (2021-2032) Figure 45. Asia Softgel CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Softgel CDMO Revenue Share by Type (2021-2032) Figure 47. Asia Softgel CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Softgel CDMO Revenue Share by Region (2021-2032) Figure 49. Japan Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Softgel CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Softgel CDMO Revenue Share by Type (2021-2032) Figure 57. SAMEA Softgel CDMO Revenue Share by Application (2021-2032) Figure 58. SAMEA Softgel CDMO Revenue Share by Country (2021-2032) Figure 59. Brazil Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Softgel CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmaceutical Softgel CDMO
  • Nutraceutical Softgel CDMO
  • Others
Applications
  • Pharmaceutical Company
  • Biotechnology Company
  • Others
Companies covered
  • Procaps
  • Patheon
  • NextPharma
  • Lonza
  • Samsung Biologics
  • Fareva
  • WuXi AppTech
  • WuXi Biologics
  • Siegfried
  • Catalent
  • Aenova
  • Sirio Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Softgel CDMO Market by Type
  3. 1.2.1 Global Softgel CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pharmaceutical Softgel CDMO
  5. 1.2.3 Nutraceutical Softgel CDMO
  6. 1.2.4 Others
  7. 1.3 Softgel CDMO Market by Application
  8. 1.3.1 Global Softgel CDMO Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Pharmaceutical Company
  10. 1.3.3 Biotechnology Company
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Softgel CDMO Market Dynamics
  1. 2.1 Softgel CDMO Industry Trends
  2. 2.2 Softgel CDMO Industry Drivers
  3. 2.3 Softgel CDMO Industry Opportunities and Challenges
  4. 2.4 Softgel CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Softgel CDMO Market Perspective (2021-2032)
  2. 3.2 Global Softgel CDMO Growth Trends by Region
  3. 3.2.1 Global Softgel CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Softgel CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Softgel CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Softgel CDMO Revenue by Players
  2. 4.1.1 Global Softgel CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Softgel CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Softgel CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Softgel CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Softgel CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Softgel CDMO Players, Product Type & Application
  8. 4.5 Global Softgel CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Softgel CDMO Market CR5 and HHI
  11. 4.6.3 2025 Softgel CDMO Tier 1, Tier 2, and Tier 3
5 Softgel CDMO Market Size by Type
  1. 5.1 Global Softgel CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Softgel CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Softgel CDMO Revenue Market Share by Type (2021-2032)
6 Softgel CDMO Market Size by Application
  1. 6.1 Global Softgel CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Softgel CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Softgel CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Procaps
  2. 7.1.1 Procaps Company Information
  3. 7.1.2 Procaps Business Overview
  4. 7.1.3 Procaps Softgel CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Procaps Softgel CDMO Product Portfolio
  6. 7.1.5 Procaps Recent Developments
  7. 7.2 Patheon
  8. 7.2.1 Patheon Company Information
  9. 7.2.2 Patheon Business Overview
  10. 7.2.3 Patheon Softgel CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Patheon Softgel CDMO Product Portfolio
  12. 7.2.5 Patheon Recent Developments
  13. 7.3 NextPharma
  14. 7.3.1 NextPharma Company Information
  15. 7.3.2 NextPharma Business Overview
  16. 7.3.3 NextPharma Softgel CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 NextPharma Softgel CDMO Product Portfolio
  18. 7.3.5 NextPharma Recent Developments
  19. 7.4 Lonza
  20. 7.4.1 Lonza Company Information
  21. 7.4.2 Lonza Business Overview
  22. 7.4.3 Lonza Softgel CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lonza Softgel CDMO Product Portfolio
  24. 7.4.5 Lonza Recent Developments
  25. 7.5 Samsung Biologics
  26. 7.5.1 Samsung Biologics Company Information
  27. 7.5.2 Samsung Biologics Business Overview
  28. 7.5.3 Samsung Biologics Softgel CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Samsung Biologics Softgel CDMO Product Portfolio
  30. 7.5.5 Samsung Biologics Recent Developments
  31. 7.6 Fareva
  32. 7.6.1 Fareva Company Information
  33. 7.6.2 Fareva Business Overview
  34. 7.6.3 Fareva Softgel CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fareva Softgel CDMO Product Portfolio
  36. 7.6.5 Fareva Recent Developments
  37. 7.7 WuXi AppTech
  38. 7.7.1 WuXi AppTech Company Information
  39. 7.7.2 WuXi AppTech Business Overview
  40. 7.7.3 WuXi AppTech Softgel CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 WuXi AppTech Softgel CDMO Product Portfolio
  42. 7.7.5 WuXi AppTech Recent Developments
  43. 7.8 WuXi Biologics
  44. 7.8.1 WuXi Biologics Company Information
  45. 7.8.2 WuXi Biologics Business Overview
  46. 7.8.3 WuXi Biologics Softgel CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 WuXi Biologics Softgel CDMO Product Portfolio
  48. 7.8.5 WuXi Biologics Recent Developments
  49. 7.9 Siegfried
  50. 7.9.1 Siegfried Company Information
  51. 7.9.2 Siegfried Business Overview
  52. 7.9.3 Siegfried Softgel CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Siegfried Softgel CDMO Product Portfolio
  54. 7.9.5 Siegfried Recent Developments
  55. 7.10 Catalent
  56. 7.10.1 Catalent Company Information
  57. 7.10.2 Catalent Business Overview
  58. 7.10.3 Catalent Softgel CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Catalent Softgel CDMO Product Portfolio
  60. 7.10.5 Catalent Recent Developments
  61. 7.11 Aenova
  62. 7.11.1 Aenova Company Information
  63. 7.11.2 Aenova Business Overview
  64. 7.11.3 Aenova Softgel CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Aenova Softgel CDMO Product Portfolio
  66. 7.11.5 Aenova Recent Developments
  67. 7.12 Sirio Pharma
  68. 7.12.1 Sirio Pharma Company Information
  69. 7.12.2 Sirio Pharma Business Overview
  70. 7.12.3 Sirio Pharma Softgel CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sirio Pharma Softgel CDMO Product Portfolio
  72. 7.12.5 Sirio Pharma Recent Developments
8 North America
  1. 8.1 North America Softgel CDMO Revenue (2021-2032)
  2. 8.2 North America Softgel CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Softgel CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Softgel CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Softgel CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Softgel CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Softgel CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Softgel CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Softgel CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Softgel CDMO Revenue by Country
  11. 8.6.1 North America Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Softgel CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Softgel CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Softgel CDMO Revenue (2021-2032)
  2. 9.2 Europe Softgel CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Softgel CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Softgel CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Softgel CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Softgel CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Softgel CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Softgel CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Softgel CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Softgel CDMO Revenue by Country
  11. 9.6.1 Europe Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Softgel CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Softgel CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Softgel CDMO Revenue (2021-2032)
  2. 10.2 China Softgel CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Softgel CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Softgel CDMO Revenue by Type (2027-2032)
  5. 10.3 China Softgel CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Softgel CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Softgel CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Softgel CDMO Revenue by Application (2027-2032)
  9. 10.5 China Softgel CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Softgel CDMO Revenue (2021-2032)
  2. 11.2 Asia Softgel CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Softgel CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Softgel CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Softgel CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Softgel CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Softgel CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Softgel CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Softgel CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Softgel CDMO Revenue by Country
  11. 11.6.1 Asia Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Softgel CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Softgel CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Softgel CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Softgel CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Softgel CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Softgel CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Softgel CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Softgel CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Softgel CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Softgel CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Softgel CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Softgel CDMO Revenue by Country
  11. 12.6.1 SAMEA Softgel CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Softgel CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Softgel CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst